Přínos a rizika léčby clopidogrelem u pacientů s koronární nemocí: důkazy z randomizovaných studií a z registrů

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F08%3A00000897" target="_blank" >RIV/00216208:11120/08:00000897 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/08:#0000354

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Benefits and Risks of clopidogrel use in Patients with Coronary Artery Disease: Evidence from Randomized Studies and Registries

Popis výsledku v původním jazyce

Background: Aggressive antiplatelet treatment is currently an established practice in patients with coronary artery disease. Objective: This article discusses the evidence from clinical trials and registries concerning the benefits and risks of clopidogrel in relation to the dose and timing of treatment and its use in particular patient populations (stratified by risk factors for major adverse cardiovascular events). Methods: Human clinical trials, registries, and in vitro human platelet studies were identified through searches of MEDLINE, Scopus, Google Scholar, and ClinicalTrials.gov (January 1980-July 2008) using the terms clopidogrel in coronary artery disease, clopidogrel loading dose, clopidogrel pretreatment, and antiplatelet therapy for coronary artery disease. For inclusion in the review, publications had to compare clopidogrel administered at different doses and times across the spectrum of patients with coronary artery disease; present outcome data on mortality, reinfarction

Název v anglickém jazyce

Benefits and Risks of clopidogrel use in Patients with Coronary Artery Disease: Evidence from Randomized Studies and Registries

Popis výsledku anglicky

Background: Aggressive antiplatelet treatment is currently an established practice in patients with coronary artery disease. Objective: This article discusses the evidence from clinical trials and registries concerning the benefits and risks of clopidogrel in relation to the dose and timing of treatment and its use in particular patient populations (stratified by risk factors for major adverse cardiovascular events). Methods: Human clinical trials, registries, and in vitro human platelet studies were identified through searches of MEDLINE, Scopus, Google Scholar, and ClinicalTrials.gov (January 1980-July 2008) using the terms clopidogrel in coronary artery disease, clopidogrel loading dose, clopidogrel pretreatment, and antiplatelet therapy for coronary artery disease. For inclusion in the review, publications had to compare clopidogrel administered at different doses and times across the spectrum of patients with coronary artery disease; present outcome data on mortality, reinfarction

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Therapeutics

ISSN

0149-2918

e-ISSN

—

Svazek periodika

8

Číslo periodika v rámci svazku

Sp. Iss. 2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

12

Strana od-do

—

Kód UT WoS článku

000262062900002

EID výsledku v databázi Scopus

—